FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.
Ovarian cancer (OC) is a leading cause of cancer mortality, but aside from a few well-studied mutations, very little is known about its underlying causes. As such, we performed survival analysis on ovarian copy number amplifications and gene expression datasets presented by The Cancer Genome Atlas in order to identify potential drivers and markers of aggressive OC. Additionally, two independent datasets from the Gene Expression Omnibus web platform were used to validate the identified markers. Based on our analysis, we identified FXYD5, a glycoprotein known to reduce cell adhesion, as a potential driver of metastasis and a significant predictor of mortality in OC. As a marker of poor outcome, the protein has effective antibodies against it for use in tissue arrays. FXYD5 bridges together a wide variety of cancers, including ovarian, breast cancer stage II, thyroid, colorectal, pancreatic, and head and neck cancers for metastasis studies.
School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, USA ; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, PA, USA ; Fara Diagnostics, Philadelphia, PA, USA.
Pichai
P
Raman
School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, USA.
Timothy
T
Purwin
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Richard
R
Pestell
School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, USA.
Aydin
A
Tozeren
FXYD5; TCGA; dysadherin; ovarian cancer; survival